Last $17.60 USD
Change Today +0.10 / 0.57%
Volume 292.5K
DVAX On Other Exchanges
Symbol
Exchange
Frankfurt
As of 5:20 PM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

dynavax technologies corp (DVAX) Snapshot

Open
$17.52
Previous Close
$17.50
Day High
$17.72
Day Low
$17.38
52 Week High
03/5/14 - $20.90
52 Week Low
05/8/14 - $12.50
Market Cap
462.8M
Average Volume 10 Days
239.2K
EPS TTM
$-3.29
Shares Outstanding
26.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for DYNAVAX TECHNOLOGIES CORP (DVAX)

dynavax technologies corp (DVAX) Related Businessweek News

No Related Businessweek News Found

dynavax technologies corp (DVAX) Details

Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops products to prevent and treat infectious and inflammatory diseases, and cancer. It develops product candidates based on the use of immunostimulatory sequences and immunoregulatory sequences. Its lead product candidate is HEPLISAV, a investigational adult hepatitis B vaccine which is in Phase III clinical trials. The company also develops DV1179, a TLR inhibitor of TLR 7 and TLR9 for the treatment of autoimmune and inflammatory diseases that is in Phase I clinical trials; AZD1419, a candidate drug for the treatment of asthma, which is in Phase I clinical trials; SD-101, a second-generation TLR 9 agonist for immunotherapy of cancer that is in Phase I clinical trials; and DV230, an adjuvant platform that is in preclinical studies. It has a strategic alliance with GlaxoSmithKline to discover, develop, and commercialize TLR inhibitors; and a research collaboration and license agreement with AstraZeneca AB for the discovery and development of TLR9 agonist-based therapies for the treatment of asthma and chronic obstructive pulmonary disease. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was founded in 1996 and is based in Berkeley, California.

151 Employees
Last Reported Date: 03/10/14
Founded in 1996

dynavax technologies corp (DVAX) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $533.3K
Principal Financial Officer, Chief Business O...
Total Annual Compensation: $342.2K
Senior Vice President of Operations and Quali...
Total Annual Compensation: $305.8K
Chief Medical Officer and Vice President of C...
Total Annual Compensation: $323.9K
Chief Scientific Officer and Vice President
Total Annual Compensation: $282.6K
Compensation as of Fiscal Year 2013.

dynavax technologies corp (DVAX) Key Developments

Dynavax Technologies Corporation Presents at RBC Capital Markets Healthcare Conference 2015, Feb-24-2015 09:30 AM

Dynavax Technologies Corporation Presents at RBC Capital Markets Healthcare Conference 2015, Feb-24-2015 09:30 AM. Venue: The New York Palace Hotel, New York, New York, United States. Speakers: Eddie Gray, Chief Executive Officer and Director.

Dynavax Technologies Corporation Announces Board Changes

Dynavax Technologies Corporation announced the appointment of Laura Brege to its Board of Directors and Audit Committee. Denise Gilbert, a director and the Chair of the Audit Committee since 2004, will retire from her positions with the company following the next Audit Committee meeting, whereupon Ms. Brege will become Chair of the Committee. Ms. Brege is President and Chief Executive Officer of Nodality Inc. She has over 20 years of executive management experience in the pharmaceutical, biotechnology and venture capital industries. Prior to joining Nodality in 2012, Ms. Brege held several senior-level positions at Onyx Pharmaceuticals Inc., including Executive Vice President and Chief Operating OfficerPrior to Onyx, Ms. Brege was a General Partner at Red Rock Capital Management. Previously, Ms. Brege was SVP and Chief Financial Officer at COR Therapeutics.

Dynavax Technologies Corporation Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-15-2015 10:00 AM

Dynavax Technologies Corporation Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-15-2015 10:00 AM. Venue: Westin St. Francis Hotel, San Francisco, California, United States. Speakers: Eddie Gray, Chief Executive Officer and Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DVAX:US $17.60 USD +0.10

DVAX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Advaxis Inc $9.00 USD -0.73
Argos Therapeutics Inc $9.02 USD -0.13
Genocea Biosciences Inc $8.63 USD -0.45
Inovio Pharmaceuticals Inc $7.08 USD +0.045
Peregrine Pharmaceuticals Inc $1.41 USD +0.03
View Industry Companies
 

Industry Analysis

DVAX

Industry Average

Valuation DVAX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 39.7x
Price/Book 3.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 28.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DYNAVAX TECHNOLOGIES CORP, please visit www.dynavax.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.